The global focal segmental glomerulosclerosis (FSGS) market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market include the increasing prevalence of FSGS, rising focus towards rare diseases, and increasing R&D activity. Moreover, in both developed and emerging markets, increasing demand for the kidney transplants and a higher rate of hospitalizations have been witnessed, due to kidney malfunction. This increases the demand for diagnosis of the initial stage of FSGS diseases during the treatment of kidney diseases. Thus, the burden of glomerulus-related disorders drives the global FSGS market during the forecast period. FSGS is the progressive scarring of the kidney, which is characterized by proteinuria. It is among the rare diseases, which affects kidney function by attacking and damaging the glomeruli. This disease is characterized by kidney defects by birth, obesity, obstructive sleep apnea, sickle cell anemia, viruses, such as HIV, among others.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/focal-segmental-glomerulosclerosis-market
Primary FSGS has become one of the most common causes of idiopathic glomerular disease in adults. The primary FSGS is usually idiopathic, which refers to the rise of disease without any known, definite or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. The current therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the emerging companies having their potential drug candidates in the pipeline which include Chemocentryx, Reata, Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals. Since it is a rare disease, specialty clinical-stage companies are likely to get more funds that can leverage the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments, which in turn, is expected to fuel the growth of the global focal segmental glomerulosclerosis market.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Disease Type
o By Disease Management
o By Treatment
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: Novartis International AG, Variant Pharmaceuticals, Inc., and AbbVie Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Focal Segmental Glomerulosclerosis Market Report by Segment
By Disease Type
- Primary FSGS
- Secondary FSGS
By Disease Management
- Diagnosis
o Kidney Biopsy
o Creatinine Test
o Other Diagnosis
- Treatment
o Drug Therapy
o Dialysis
o Kidney Transplant
A full report of Focal Segmental Glomerulosclerosis Market is available at: https://www.omrglobal.com/industry-reports/focal-segmental-glomerulosclerosis-market
Focal Segmental Glomerulosclerosis Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Novartis International AG
- Variant Pharmaceuticals, Inc.
- AbbVie Inc.
